None listed
Conditions
Interventions
Romiplostim is supplied in a 5 mL single-use vial as a sterile, white, preservative-free, lyophilized powder containing a protein concentration of 0.5 mg/mL of 10 mM histidine, 4.0% mannitol, 2.0% suc
g/kg based on the subject’s recorded screening weight. Initially, IP will be administered in the clinic by a qualified health care provider and subjects will return to the clinic weekly to provide blo
g/kg up to a maximum dose of 10 μ
g/kg in an attempt to reach a target platelet count of ≥
50 x 109/L. Dose adjustments will be allowed to maintain a platelet count between ≥
50 x 109/L and ≤
200 x 109/L. Dose adjustments will be evaluated every 12 weeks due to potential body weight changes.
Sponsors
AMGEN INC.,
Eligibility
Sex/Gender
All
Age
1 Years to 17 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria 4.1.1 Diagnosis of primary ITP according to The American Society of Hematology (ASH) Guidelines (Neunert et al, 2011) at least 6 months before screening, regardless of splenectomy status 4.1.2 Age ≥ 1 year and < 18 years at the time of providing informed consent 4.1.3 Subject must be refractory to a prior ITP therapy, having relapsed after at least 1 prior ITP therapy, or be ineligible for other ITP therapies Examples of prior therapy include but are not limited to: corticosteroids, IVIG, anti-D immunoglobulin, and platelet transfusions. Subjects who have failed a splenectomy are eligible for study participation 4.1.4 Subject has a documented platelet count ≤ 30 x109/L or is experiencing bleeding that is uncontrolled with conventional therapies 4.1.5 Subject’s legally acceptable representative (or subject, if applicable) has provided informed consent before any study-specific procedure; and subject has provided assent, where required by the IRB/IEC
Exclusion criteria
Exclusion criteria: Exclusion Criteria 4.2.1 Known history of a bone marrow stem cell disorder (Any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled in the study) 4.2.2 Prior bone marrow transplant or peripheral blood progenitor cell transplant 4.2.3 Known active or prior malignancy except non-melanoma skin cancers within the last 5 years 4.2.4 Known history of myelodysplastic syndrome 4.2.5 Known history of bleeding diathesis 4.2.6 Known history of congenital thrombocytopenia 4.2.7 Known history of hepatitis B, hepatitis C or human immunodeficiency virus 4.2.8 Known history of systemic lupus erythematosus, Evans syndrome, or autoimmune neutropenia 4.2.9 Known history of antiphospholipid antibody syndrome or known positive for lupus anticoagulant 4.2.10 Known history of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura 4.2.11 History of venous thromboembolism or thrombotic events 4.2.12 Previous use of romiplostim or eltrombopag 4.2.13 Previous use of PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO) or any other platelet producing agent 4.2.14 Rituximab (for any indication) or 6-mercaptopurine within 8 weeks of enrollment, or anticipated use at any time during the study 4.2.15 Splenectomy within 4 weeks of the screening visit 4.2.16 Alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study 4.2.17 Vaccinations known to decrease platelet counts within 8 weeks before the screening visit 4.2.18 Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s) 4.2.19 Subject will have investigational procedures performed while enrolled in this clinical study 4.2.20 Female subject of child bearing potential (defined as having first menses) is not willing to use, in combination with her partner highly effective methods of birth control during treatment and for 1 month after the end of treatment 4.2.21 Subject is pregnant or breast feeding, or might become pregnant within 1 month after the end of treatment 4.2.22 Subject has known hypersensitivity to any recombinant Escherichia coli derived product (eg, Infergen, Neupogen, somatropin, and Actimmune®) 4.2.23 Subject has previously enrolled into this study 4.2.24 Subject will not be available for protocol-required study visits or procedures, to the best of the subject’s and investigator’s knowledge 4.2.25 Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures
Countries
Belgium, Brazil, Bulgaria, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lithuania, Netherlands, Peru, Poland, Russian Federation, Slovakia, South Africa, Spain, Switzerland, Turkey, United Kindgdom
Contacts
Public ContactGabriela Celina Loyola
IQVIA RDS Peru S.R.L
Outcome results
None listed